QuadMedicine

QuadMedicine (쿼드메디슨) is a South Korean company specializing in microneedle-based drug delivery platforms for pharmaceuticals and medical devices. Founded in December 2016 by Baek Seung-ki, who holds a bachelor's degree in electronics engineering and a master's degree in biomedical engineering from Gachon University, the company is headquartered in South Korea. Its core business model focuses on contract manufacturing and technology transfer rather than direct drug development. The company has developed three proprietary microneedle array patch technologies: S-MAP (Separable Microneedle Array Patch), where drug-containing microneedle tips detach upon skin insertion and are absorbed into the body; C-MAP (Coated Microneedle Array Patch), where liquid vaccines or drugs are precisely coated onto microneedle surfaces and dissolve upon reaching the dermis; and P-MAP (Powder-attached Microneedle Array Patch), where solidified drug particles are attached to needle tips. QuadMedicine has established partnerships with major pharmaceutical companies. In 2020, it signed a memorandum of understanding (MOU) with LG Chem for microneedle vaccine clinical trials. In 2022, Kwangdong Pharmaceutical invested 2 billion won in the company, and QuadMedicine transferred microneedle osteoporosis treatment technology to Hanlim Pharm. The company received BBB ratings from Nice Information Service and the Korea Invention Promotion Association in 2023, followed by A ratings from Nice Information Service and iCredible in 2025. In September 2025, it passed the KOSDAQ preliminary listing review and listed on the KOSDAQ market on December 12, 2025.

QuadMedicine was founded in December 2016 by Baek Seung-ki, who graduated from Gachon University with a bachelor's degree in electronics engineering and a master's degree in biomedical engineering. The company was established to commercialize microneedle-based drug delivery technologies. In 2020, QuadMedicine signed a memorandum of understanding (MOU) with LG Chem to conduct clinical trials for a microneedle-based vaccine. This partnership marked a significant step in validating the company's platform technology. In 2022, Kwangdong Pharmaceutical invested 2 billion won in QuadMedicine, and the company transferred its microneedle osteoporosis treatment technology to Hanlim Pharm. These deals demonstrated growing industry recognition of QuadMedicine's microneedle platforms. In 2023, QuadMedicine received BBB ratings from Nice Information Service and the Korea Invention Promotion Association in technology evaluations. By 2025, the company improved its ratings to A from Nice Information Service and iCredible. In September 2025, QuadMedicine passed the KOSDAQ preliminary listing review, and on December 12, 2025, it listed on the KOSDAQ market, providing capital for further development and commercialization of its microneedle technologies.

• Founded by Baek Seung-ki

• Signed MOU with LG Chem for microneedle vaccine clinical trials

• Kwangdong Pharmaceutical invested 2 billion won

• Transferred microneedle osteoporosis treatment technology to Hanlim Pharm

• Received BBB ratings from Nice Information Service and Korea Invention Promotion Association

• Received A ratings from Nice Information Service and iCredible

• Passed KOSDAQ preliminary listing review

• Listed on KOSDAQ

Microneedle platform specialist for drug delivery, focusing on contract manufacturing and technology transfer.

• S-MAP (Separable Microneedle Array Patch)

  Drug-containing microneedle tips detach upon skin insertion and are absorbed into the body.

• C-MAP (Coated Microneedle Array Patch)

  Liquid vaccines or drugs are precisely coated onto microneedle surfaces and dissolve upon reaching the dermis.

• P-MAP (Powder-attached Microneedle Array Patch)

  Solidified drug particles are attached to needle tips.

1. 1쿼드메디슨 | QuadMedicinequadmedicine.com
2. 2쿼드메디슨 - 위키백과ko.wikipedia.org
3. 3quadmedicine - Wikidatawikidata.org